KALA BIO
135 Beaver Street
Suite 309
Waltham
Massachusetts
02452
United States
Tel: 781-996-5252
Fax: 781-642-0399
Website: http://www.kalarx.com/
Email: info@kalarx.com
204 articles about KALA BIO
-
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August
8/4/2021
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in August.
-
Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call
7/29/2021
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021.
-
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - July 19, 2021
7/19/2021
Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.
-
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - June 18, 2021
6/18/2021
Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.
-
Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx
6/3/2021
Kala Pharmaceuticals, Inc., today announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021.
-
Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference
5/27/2021
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2021 Virtual Healthcare Conference. Management is scheduled to participate in a fireside chat on Thursday, June 3, 2021 at 10:00 am ET.
-
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 20, 2021
5/20/2021
Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company's 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.
-
Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference
5/6/2021
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the BofA Securities 2021 Healthcare Conference. Management is scheduled to participate in a Fireside Chat on Thursday, May 13, 2021 at 4:15 pm ET.
-
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
5/5/2021
-- Achieved $3.3 Million in Net Revenue in First Quarter -- -- Launched EYSUVIS® and Expanded Commercial Coverage to More than 69 Million Commercial Lives -- -- New Credit Facility Provides up to $125M -- -- Cash Runway Projected for at Least Two Years -- -- Conference Call and Webcast at 8:00 a.m. ET --
-
Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call
4/28/2021
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021.
-
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Mar 18, 2021
3/18/2021
Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.
-
Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna
3/16/2021
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Cigna has added EYSUVIS
-
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March 2021
3/2/2021
Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, announced that management will participate in the following virtual healthcare investor conferences in March.
-
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
2/25/2021
-- Launched EYSUVIS™, First and Only Prescription Therapy Approved Specifically for Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease -- -- Progressing Pipeline Programs to Address Front and Back of Eye Diseases -- -- Cash Position and INVELTYS Revenue Expected to Provide Runway Into at Least 4Q 2022; EYSUVIS Revenue Expected to Provide Additional Runway --
-
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call
2/18/2021
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021
-
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Feb 17, 2021
2/17/2021
Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.
-
Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts
2/16/2021
Kala Pharmaceuticals Announces EYSUVIS ™ Now Covered by Express Scripts Express Scripts coverage effective February 5, 2021 WATERTOWN, Mass.--( BUSINESS WIRE )-- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Express Scripts, one of the leading pharmacy benefit managers (PBM) in the United States, h
-
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Jan 20, 2021
1/20/2021
Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.
-
Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline
1/7/2021
Kala Pharmaceuticals Announces Availability of EYSUVIS TM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline -- First and only prescription therapy approved specifically for short-term treatment of the signs and symptoms of dry eye disease now available in pharmacies nationwide -- -- Advancing multiple NCE development programs targeted to address front and back of eye diseases --
-
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January
1/4/2021
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will participate in two investor conferences in January. Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present at the 39 th Annual J.P. Morgan Healthcare Conference on We